1. Scrip

Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra

 
• By Sue Sutter

Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
Pfizer's Ixifi is the first US approval of a biosimilar wholly developed by the big pharma.

Pfizer Inc.'s Ixifi, a biosimilar version of Janssen Biotech Inc.'s tumor necrosis factor inhibitor Remicade (infliximab), received FDA approval Dec. 13, but the big pharma, which already markets an infliximab biosimilar, is not planning to compete against itself for now.

Ixifi (infliximab-qbtx) is approved for all of the eligible indications on the Remicade label: adult and pediatric Crohn's disease, ulcerative...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.